Associations of menopause transition and menopause pharmacotherapies with onset, exacerbation/improvement, and management of mental disorders
Meno2mind is an evidence synthesis project founded by Alexis Cullen at the Karolinska Institute, Stockholm. Collaborators include: Claudia Cepeda-Lopez, Susan Mylchreest, Mahira Budhraja, Jo Burgin, Laura Hanley, Lynsay Matthews, Yvette Pyne, Thomas Reilly, and Gemma Sharp.
The protocol is available here.
Meno2mind is a multiphase, evidence synthesis project comprising a series of sequential review projects designed to identify gaps in the current evidence base and determine the extent to which menopause transition and pharmacotherapies for menopause are associated with onset, exacerbation/improvement, and treatment of mental disorders.
These reviews will address the following research questions:
1. To what extent are menopause transition and menopause pharmacotherapies associated with the onset of mental disorders?
2. Among those with existing mental disorders, are menopause transition and menopause pharmacotherapies associated with exacerbation/improvement of illness?
3. Do menopause transition and menopause pharmacotherapies moderate the effect of treatments for mental disorders?
These research questions will be addressed using a multiphase review project comprising:
Phase 1: An initial scoping review, with a broad remit, to track the publication of studies examining the association between menopause transition/menopause pharmacotherapies and mental disorders (onset, exacerbation/improvement, and treatment) over time and to identify gaps in the literature.
Phase 2: A series of systematic reviews and meta-analyses (where possible) which address research questions identified in phase 1. These reviews will include a subset of studies identified in phase 1 and will be restricted to specific exposures (e.g., early menopause), mental disorders (e.g., psychotic disorders), and/or study designs (e.g., prospective only) guided by the quantity and quality of evidence available on specific topics.
Phase 3: An umbrella review of systematic reviews (including those conducted in phase 2 and existing/new reviews) examining the association between menopause transition/menopause pharmacotherapies and mental disorders.
4m 